Searched for: in-biosketch:yes
person:aifani01
Leukemogenic Kras mutation reprograms multipotent progenitors to facilitate its spread through the hematopoietic system
Jang, Geunhyo; Park, Rosa; Esteva, Eduardo; Hsu, Pei-Feng; Feng, Jue; Upadhaya, Samik; Sawai, Catherine M; Aifantis, Iannis; Fooksman, David R; Reizis, Boris
Leukemia-driving mutations are thought to arise in hematopoietic stem cells (HSC), yet the natural history of their spread is poorly understood. We genetically induced mutations within endogenous murine HSC and traced them in unmanipulated animals. In contrast to mutations associated with clonal hematopoiesis (such as Tet2 deletion), the leukemogenic KrasG12D mutation dramatically accelerated HSC contribution to all hematopoietic lineages. The acceleration was mediated by KrasG12D-expressing multipotent progenitors (MPP) that lacked self-renewal but showed increased proliferation and aberrant transcriptome. The deletion of osteopontin, a secreted negative regulator of stem/progenitor cells, delayed the early expansion of mutant progenitors. KrasG12D-carrying cells showed increased CXCR4-driven motility in the bone marrow, and the blockade of CXCR4 reduced the expansion of MPP in vivo. Finally, therapeutic blockade of KRASG12D spared mutant HSC but reduced the expansion of mutant MPP and their mature progeny. Thus, transforming mutations facilitate their own spread from stem cells by reprogramming MPP, creating a preleukemic state via a two-component stem/progenitor circuit.
PMCID:11899982
PMID: 40072317
ISSN: 1540-9538
CID: 5808472
The rewired immune microenvironment in leukemia
Ciantra, Zoe; Paraskevopoulou, Varvara; Aifantis, Iannis
Leukemias are a class of human cancers that originate from hematopoietic progenitors and are characterized by extensive remodeling of the immune microenvironment. Leukemic cells, on transformation, acquire the ability to evade immune recognition but, despite undergoing genetic and epigenetic changes, retain their characteristic immature immune signature. For this and other reasons, leukemias are often refractory to immune therapies. In the present Review, we cover these areas as a means of improving outcomes from a deeper understanding of immune rewiring, inflammatory signaling and the barriers to successful implementation of immune therapies.
PMID: 40021898
ISSN: 1529-2916
CID: 5801512
The common murine retroviral integration site activating Hhex marks a distal regulatory enhancer co-opted in human Early T-cell precursor leukemia
Hardwick, Joyce; Rodriguez-Hernaez, Javier; Gambi, Giovanni; Venters, Bryan J; Guo, Yan; Li, Liqi; Love, Paul E; Copeland, Neal G; Jenkins, Nancy A; Papaioannou, Dimitrios; Aifantis, Iannis; Tsirigos, Aristotelis; Ivan, Mircea; Davé, Utpal P
The Hhex gene encodes a transcription factor that is important for both embryonic and post-natal development, especially of hematopoietic tissues. Hhex is one of the most common sites of retroviral integration in mouse models. We found the most common integrations in AKXD (recombinant inbred strains) T-ALLs occur 57-61kb 3' of Hhex and activate Hhex gene expression. The genomic region of murine leukemia virus (MLV) integrations has features of a developmental stage-specific cis regulatory element (CRE), as evidenced by ATAC-seq in murine progenitor cells and high H3K27 acetylation at the syntenic CRE in human hematopoietic cell lines. With ChIP-exonuclease, we describe occupancy of LIM domain binding protein 1 (LDB1), the constitutive partner of the LIM Only-2 (LMO2), GATA1, and TAL1 transcription factors at GATA sites and a composite GATA-E box within the CRE. With virtual 4C analysis, we observed looping between this +65kb CRE and the proximal intron 1 enhancer of HHEX in primary human ETP-ALLs and in normal progenitor cells. Our results show that retroviral integrations at intergenic sites can mark and take advantage of CREs. Specifically, in the case of HHEX activation, this newly described +65kb CRE is co-opted in the pathogenesis of ETP-ALL by the LMO2/LDB1 complex.
PMID: 39880094
ISSN: 1083-351x
CID: 5780992
Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs
Allman, Anneka; Gaudette, Brian T; Kelly, Samantha; Alouche, Nagham; Carrington, Léolène J; Perkey, Eric; Brandstadter, Joshua D; Outen, Riley; Vanderbeck, Ashley; Lederer, Katlyn; Zhou, Yeqiao; Faryabi, Robert B; Robertson, Tanner F; Burkhardt, Janis K; Tikhonova, Anastasia; Aifantis, Iannis; Scarpellino, Leonardo; Koch, Ute; Radtke, Freddy; Lütge, Mechthild; De Martin, Angelina; Ludewig, Burkhard; Tveriakhina, Lena; Gossler, Achim; Mosteiro, Lluc; Siebel, Christian W; Gómez Atria, Daniela; Luther, Sanjiv A; Allman, David; Maillard, Ivan
Innate-like splenic marginal zone (MZ) B (MZB) cells play unique roles in immunity due to their rapid responsiveness to blood-borne microbes. How MZB cells integrate cell-extrinsic and -intrinsic processes to achieve accelerated responsiveness is unclear. We found that Delta-like1 (Dll1) Notch ligands in splenic fibroblasts regulated MZB cell pool size, migration, and function. Dll1 could not be replaced by the alternative Notch ligand Dll4. Dll1-Notch2 signaling regulated a Myc-dependent gene expression program fostering cell growth and a Myc-independent program controlling cell-movement regulators such as sphingosine-1 phosphate receptor 1 (S1PR1). S1pr1-deficient B cells experienced Notch signaling within B cell follicles without entering the MZ and were retained in the spleen upon Notch deprivation. Key elements of the mouse B cell Notch regulome were preserved in subsets of human memory B cells and B cell lymphomas. Thus, specialized niches program the poised state and patrolling behavior of MZB cells via conserved Myc-dependent and Myc-independent Notch2-regulated mechanisms.
PMID: 39731910
ISSN: 1097-4180
CID: 5767982
Vitamin C deprivation puts stem cells to sleep
Balandrán, Juan Carlos; Aifantis, Iannis
PMID: 39745692
ISSN: 1528-0020
CID: 5805592
3D chromatin hubs as regulatory units of identity and survival in human acute leukemia
Gambi, Giovanni; Boccalatte, Francesco; Rodriguez Hernaez, Javier; Lin, Ziyan; Nadorp, Bettina; Polyzos, Alexander; Tan, Jimin; Avrampou, Kleopatra; Inghirami, Giorgio; Kentsis, Alex; Apostolou, Effie; Aifantis, Iannis; Tsirigos, Aristotelis
Cancer progression involves genetic and epigenetic changes that disrupt chromatin 3D organization, affecting enhancer-promoter interactions and promoting growth. Here, we provide an integrative approach, combining chromatin conformation, accessibility, and transcription analysis, validated by in silico and CRISPR-interference screens, to identify relevant 3D topologies in pediatric T cell leukemia (T-ALL and ETP-ALL). We characterize 3D hubs as regulatory centers for oncogenes and disease markers, linking them to biological processes like cell division, inflammation, and stress response. Single-cell mapping reveals heterogeneous gene activation in discrete epigenetic clones, aiding in patient stratification for relapse risk after chemotherapy. Finally, we identify MYB as a 3D hub regulator in leukemia cells and show that the targeting of key regulators leads to hub dissolution, thereby providing a novel and effective anti-leukemic strategy. Overall, our work demonstrates the relevance of studying oncogenic 3D hubs to better understand cancer biology and tumor heterogeneity and to propose novel therapeutic strategies.
PMID: 39719705
ISSN: 1097-4164
CID: 5767452
The stress response regulator HSF1 modulates natural killer cell anti-tumour immunity
Hockemeyer, Kathryn; Sakellaropoulos, Theodore; Chen, Xufeng; Ivashkiv, Olha; Sirenko, Maria; Zhou, Hua; Gambi, Giovanni; Battistello, Elena; Avrampou, Kleopatra; Sun, Zhengxi; Guillamot, Maria; Chiriboga, Luis; Jour, George; Dolgalev, Igor; Corrigan, Kate; Bhatt, Kamala; Osman, Iman; Tsirigos, Aristotelis; Kourtis, Nikos; Aifantis, Iannis
Diverse cellular insults converge on activation of the heat shock factor 1 (HSF1), which regulates the proteotoxic stress response to maintain protein homoeostasis. HSF1 regulates numerous gene programmes beyond the proteotoxic stress response in a cell-type- and context-specific manner to promote malignancy. However, the role(s) of HSF1 in immune populations of the tumour microenvironment remain elusive. Here, we leverage an in vivo model of HSF1 activation and single-cell transcriptomic tumour profiling to show that augmented HSF1 activity in natural killer (NK) cells impairs cytotoxicity, cytokine production and subsequent anti-tumour immunity. Mechanistically, HSF1 directly binds and regulates the expression of key mediators of NK cell effector function. This work demonstrates that HSF1 regulates the immune response under the stress conditions of the tumour microenvironment. These findings have important implications for enhancing the efficacy of adoptive NK cell therapies and for designing combinatorial strategies including modulators of NK cell-mediated tumour killing.
PMID: 39223375
ISSN: 1476-4679
CID: 5687692
Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia
Narang, Sonali; Ghebrechristos, Yohana; Evensen, Nikki A; Murrell, Nina; Jasinski, Sylwia; Ostrow, Talia H; Teachey, David T; Raetz, Elizabeth A; Lionnet, Timothee; Witkowski, Matthew; Aifantis, Iannis; Tsirigos, Aristotelis; Carroll, William L
Relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains one of the leading causes of cancer mortality in children. We performed Hi-C, ATAC-seq, and RNA-seq on 12 matched diagnosis/relapse pediatric leukemia specimens to uncover dynamic structural variants (SVs) and 3D chromatin rewiring that may contribute to relapse. While translocations are assumed to occur early in leukemogenesis and be maintained throughout progression, we discovered novel, dynamic translocations and confirmed several fusion transcripts, suggesting functional and therapeutic relevance. Genome-wide chromatin remodeling was observed at all organizational levels: A/B compartments, TAD interactivity, and chromatin loops, including some loci shared by 25% of patients. Shared changes were found to drive the expression of genes/pathways previously implicated in resistance as well as novel therapeutic candidates, two of which (ATXN1 and MN1) we functionally validated. Overall, these results demonstrate chromatin reorganization under the selective pressure of therapy and offer the potential for discovery of novel therapeutic interventions.
PMCID:11358475
PMID: 39198446
ISSN: 2041-1723
CID: 5701942
CRISPR-inhibition screen for lncRNAs linked to melanoma growth and metastasis
Petroulia, Stavroula; Hockemeyer, Kathryn; Tiwari, Shashank; Berico, Pietro; Shamloo, Sama; Banijamali, Seyedeh Elnaz; Vega-Saenz de Miera, Eleazar; Gong, Yixiao; Thandapani, Palaniraja; Wang, Eric; Schulz, Michael; Tsirigos, Aristotelis; Osman, Iman; Aifantis, Ioannis; Imig, Jochen
UNLABELLED:Melanoma being one of the most common and deadliest skin cancers, has been rising since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays the standard-of-care of advanced melanoma is resection followed by immune checkpoint inhibition based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistances. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long non-coding RNAs (lncRNAs) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistances, however systematic screens to uncover novel functional lncRNAs are scarce. Here, we profile differentially expressed lncRNAs in patient derived short-term metastatic cultures and BRAF-MEK-inhibition resistant cells. We conduct a focused growth-related CRISPR-inhibition screen of overexpressed lncRNAs, validate and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance on melanoma. SIGNIFICANCE/UNASSIGNED:Previously considered as transcriptional noise, lncRNAs have emerged as novel players in regulating many cellular aspects in health and disease including melanoma. However, the number and as well as the extent of functional significance of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR-inhibition growths screens lowering the experimental effort. We also provide a larger resource of differentially expressed lncRNAs with potential implications in melanoma growth and invasion. Our results broaden the characterized of lncRNAs as potential targets for future therapeutic applications.
PMCID:11361079
PMID: 39211068
ISSN: 2692-8205
CID: 5705472
Hematopoietic Clonal Evolution Goes Spatial [Comment]
Austin, Rebecca; Aifantis, Iannis
The spatial distribution of cells carrying clonal hematopoiesis mutations in the bone marrow and the potential role of interactions with the microenvironment are largely unknown. This study takes clonal evolution to the spatial level by describing a novel technique examining the spatial location of mutated clones in the bone marrow and the first evidence that mutated hematopoietic clones are spatially constrained and have heterogenous locations within millimeters of distance. See related article by Young et al., p. 153 (10).
PMID: 38651690
ISSN: 2643-3249
CID: 5657592